References
1. Schwedt TJ, Demaerschalk BM, Dodick DW. 2008. Patent foramen ovale
and migraine: a quantitative systematic review. Cephalalgia 28:531-540.
https://doi: 10.1111/j.1468-2982.2008.01554.
2. Riederer F, Baumgartner H, Sándor PS, Wessely P, Wöber C. 2011.
Headache in 25 consecutive patients with atrial septal defects before
and after percutaneous closure–a prospective case series. Headache
51:1297-1304. https://doi:10.1111/j.1526-4610.2010.01824.
3. Kumar P, Kijima Y, West BH, Tobis JM. 2019. The Connection Between
Patent Foramen Ovale and Migraine. Neuroimaging Clin N Am 29:261-270.
https://doi: 10.1016/j.nic.2019.01.006.
4. Tobis JM, Charles A, Silberstein SD, et al. 2017. Percutaneous
Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM
Trial. J Am Coll Cardiol 70:2766-2774. https://doi:
10.1016/j.jacc.2017.09.1105.
5. Mattle HP, Evers S, Hildick-Smith D, et al. 2016. Percutaneous
closure of patent foramen ovale in migraine with aura, a randomized
controlled trial. Eur Heart J 37:2029-2036. https://doi:
10.1093/eurheartj/ehw027.
6. Dowson A, Mullen MJ, Peatfield R, et al. 2008. Migraine Intervention
With STARFlex Technology (MIST) trial: a prospective, multicenter,
double-blind, sham-controlled trial to evaluate the effectiveness of
patent foramen ovale closure with STARFlex septal repair implant to
resolve refractory migraine headache. Circulation 117:1397-1404.
https://doi: 10.1161/CIRCULATIONAHA.107.727271.
7. Pradat P, Francannet C, Harris JA, Robert E. 2003. The epidemiology
of cardiovascular defects, part I: a study based on data from three
large registries of congenital malformations. Pediatr Cardiol
24:195-221. https://doi: 10.1007/s00246-002-9401-6.